Follow Best Investments AlertsStart the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Earlier this week, I promised you I'd be back with "three hand-selected investments that you can buy now to lead you out of" the sell-off we've been seeing over the past week or so.
Today, I'm keeping that promise.
But first, a quick story.
At a cocktail party the other night, my friend Dave pulled me aside and sheepishly admitted that he has sat out one of the best generational bull markets for tech we've ever seen.
When it comes to building their net worth, a lot of folks are like Dave.
For him, it wasn't for lack of interest. It's just, in his late 50s, he's been focused on getting his kids through private high school and college.
Now that funds are starting to free up, he wanted my opinion on how to get back into the market.
Like my mother-in-law often says, "No shame, no blame."
So instead of chiding him, I told him the same thing I tell all new investors – and folks looking to get restarted after a sell-off: You should start with exchange-traded funds (ETFs), and you should make sure you have solid exposure to technology and the life sciences.
While it may sound simple in theory, putting that into practice can be confusing. That's because there are now some 2,000 ETFs comprising more than $4 trillion in assets under management.
Crucial: This “Misunderstood” Industry Could Singlehandedly Double or Triple Your Profits
With that in mind, today I'm going to share three of my favorite ETFs.
All three of them roughly doubled the market over the past year.
And all three could do it again in the next year…
From Zero to Thousands in 25 Years
It's easy to forget just how big a deal ETFs have become. Fact is, this very popular investment vehicle didn't even exist until January 1993.
But the launch of the SPDR S&P 500 ETF (NYSE: SPY) was a game changer. It gave retail investors a way to play the benchmark S&P 500 with very little money to start with and an expense ratio approaching "free" – a mere 0.09%.
(A low expense ratio is one of the three ETF Profit Screens we use when searching for funds to buy.)
No wonder ETFs have become so popular, growing at nearly 19% a year. And there's plenty of growth ahead. The sector could be worth $20 trillion by 2027 – up from $4.57 trillion at the end of 2017.
Here at Strategic Tech Investor, we are big believers in starting with ETFs – and then adding great stocks down the road.
Here's the thing: With so many choices, it can be daunting for those who are just getting started.
With that in mind, I want to take a moment to show you three that I think are great for building wealth.
Take a look…
Sell-Off Recovery Tech ETF No. 1: The FANGs – and More
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.